報價延遲最少15分鐘:2024/12/24 12:19 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
14.57 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-17.59/-4.09
|
|
企業價值
703.79M
|
| 資產負債 |
|
每股賬面淨值
8.71
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 12:19 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies. |